5-MeO-xxT + 4mmc

[utaninja]

Discussed in #264

5-MeO-xxT + 4mmc
Dangerous
There is a significant risk of serotonin syndrome from this interaction and along with an increase in neurotoxicity.

Altuncı, Y. A., Aydoğdu, M., Açıkgöz, E., Güven, Ü., Düzağaç, F., Atasoy, A., Dağlıoğlu, N., & Annette Akgür, S. (2021). New Psychoactive Substance 5-MeO-MiPT In vivo Acute Toxicity and Hystotoxicological Study. Balkan Medical Journal, 38(1), 34–42. https://doi.org/10.4274/balkanmedj.galenos.2020.2019.11.68

Compton, D. M., Selinger, M. C., Westman, E., & Otero, P. (2011). Differentiation of MDMA or 5-MeO-DIPT induced cognitive deficits in rat following adolescent exposure. Psychology & Neuroscience, 4(1), 157–169. https://doi.org/10.3922/j.psns.2011.1.018

Dargan, P. I., Sedefov, R., Gallegos, A., & Wood, D. M. (2011). The pharmacology and toxicology of the synthetic cathinone mephedrone (4‐methylmethcathinone). Drug Testing and Analysis, 3(7–8), 454–463. https://doi.org/10.1002/dta.312

Ermakova, A. O., Dunbar, F., Rucker, J., & Johnson, M. W. (2022). A narrative synthesis of research with 5-MeO-DMT. Journal of Psychopharmacology, 36(3), 273–294. https://doi.org/10.1177/02698811211050543

Halberstadt, A. L. (2016). Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine. Pharmacology, Biochemistry, and Behavior, 143, 1–10. https://doi.org/10.1016/j.pbb.2016.01.005

Kehr, J., Ichinose, F., Yoshitake, S., Goiny, M., Sievertsson, T., Nyberg, F., & Yoshitake, T. (2011). Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats: Mephedrone increases both DA and 5-HT in rat brain. British Journal of Pharmacology, 164(8), 1949–1958. https://doi.org/10.1111/j.1476-5381.2011.01499.x

Kozell, L. B., Eshleman, A. J., Swanson, T. L., Bloom, S. H., Wolfrum, K. M., Schmachtenberg, J. L., Olson, R. J., Janowsky, A., & Abbas, A. I. (2023). Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT)2A Receptor (5-HT2AR), 5-HT2CR, 5-HT1AR, and Serotonin Transporter. The Journal of Pharmacology and Experimental Therapeutics, 385(1), 62–75. https://doi.org/10.1124/jpet.122.001454

Nagai, F., Nonaka, R., & Satoh Hisashi Kamimura, K. (2007). The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. European Journal of Pharmacology, 559(2), 132–137. https://doi.org/10.1016/j.ejphar.2006.11.075

Noworyta-Sokołowska, K., Kamińska, K., Kreiner, G., Rogóż, Z., & Gołembiowska, K. (2016). Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats. Neurotoxicity Research, 30(4), 606–619. https://doi.org/10.1007/s12640-016-9654-0

Ott, J. (2001). Pharmepéna-Psychonautics: Human Intranasal, Sublingual and Oral Pharmacology of 5-Methoxy-N, N-Dimethyl-Tryptamine. Journal of Psychoactive Drugs, 33(4), 403–407. https://doi.org/10.1080/02791072.2001.10399925

Papaseit, E., Moltó, J., Muga, R., Torrens, M., De La Torre, R., & Farré, M. (2016). Clinical Pharmacology of the Synthetic Cathinone Mephedrone. In M. H. Baumann, R. A. Glennon, & J. L. Wiley (Eds.), Neuropharmacology of New Psychoactive Substances (NPS) (Vol. 32, pp. 313–331). Springer International Publishing. https://doi.org/10.1007/7854_2016_61

Puigseslloses, P., Nadal-Gratacós, N., Ketsela, G., Weiss, N., Berzosa, X., Estrada-Tejedor, R., Islam, M. N., Holy, M., Niello, M., Pubill, D., Camarasa, J., Escubedo, E., Sitte, H. H., & López-Arnau, R. (2024). Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties. Molecular Psychiatry, 29(8), 2346–2358. https://doi.org/10.1038/s41380-024-02506-8

Ragnhildstveit, A., Khan, R., Seli, P., Bass, L. C., August, R. J., Kaiyo, M., Barr, N., Jackson, L. K., Gaffrey, M. S., Barsuglia, J. P., & Averill, L. A. (2023). 5-MeO-DMT for post-traumatic stress disorder: a real-world longitudinal case study. Frontiers in Psychiatry, 14, 1271152. https://doi.org/10.3389/fpsyt.2023.1271152

Reckweg, J. T., Uthaug, M. V., Szabo, A., Davis, A. K., Lancelotta, R., Mason, N. L., & Ramaekers, J. G. (2022). The clinical pharmacology and potential therapeutic applications of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT). Journal of Neurochemistry, 162(1), 128–146. https://doi.org/10.1111/jnc.15587

Rickli, A., Moning, O. D., Hoener, M. C., & Liechti, M. E. (2016). Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. European Neuropsychopharmacology, 26(8), 1327–1337. https://doi.org/10.1016/j.euroneuro.2016.05.001